Arcutis Biotherapeutics (ARQT) is back in focus after supporting a new American Journal of Clinical Dermatology manuscript that provides practical guidance on diagnosing and managing genital psoriasis across age groups, highlighting the company’s role in clinician education.

Despite attention on the new genital psoriasis guidance and recent restricted stock unit grants, Arcutis Biotherapeutics’ share price, at US$21.23, has fallen sharply year to date. Multi year total shareholder returns remain strongly positive, suggesting earlier investors have seen meaningful gains even as recent momentum has softened.

If this dermatology story has you thinking about other healthcare opportunities tied to new treatments and clinical data, it could be worth scanning 39 healthcare AI stocks

With the stock down 27% year to date but multiyear returns still strongly positive, Arcutis Biotherapeutics sits at an interesting crossroads. Is this pullback a chance to gain exposure to its dermatology pipeline, or is the market already pricing in future growth?

Most Popular Narrative: 46.9% Undervalued

Arcutis Biotherapeutics’ most followed narrative pegs fair value at $39.99 per share versus the last close at $21.23, framing a wide valuation gap that hinges on how durable ZORYVE’s rollout and cash generation could be.

It is almost impossible to obtain a drug label from the FDA for pediatric use, this topical non steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.

Curious what earnings profile could support that kind of gap between price and fair value? The narrative leans on strong revenue growth, rising margins, and a higher future profit multiple tied to ZORYVE’s uptake and eventual profitability. The exact hurdles and assumptions sit inside the full narrative.

Result: Fair Value of $39.99 (UNDERVALUED)

However, readers should weigh execution and funding risks, including the possibility of ZORYVE uptake falling short of expectations and the company needing more capital if cash flows lag.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With the story so focused on potential rewards, it makes sense to move quickly and stress test the thesis against the underlying data yourself. To see exactly what the market is optimistic about, review the 5 key rewards.

Looking for more investment ideas?

If Arcutis has caught your attention, do not stop here; widen your watchlist with a few focused screeners that surface different kinds of opportunities other investors might overlook.

• Target potential upside by reviewing companies our valuation filters flag as mispriced using the 48 high quality undervalued stocks.
• Prioritise resilience by scanning stocks identified for having stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by checking a screener containing 21 high quality undiscovered gems before these ideas sit firmly on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.